Announcement on Expected Increase in Semi-annual Performance for 2025
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Expected Increase in Semi-annual Performance for 2025
Filed with SSE · · 2 pages · Chinese
Release
North China Pharmaceutical Company Ltd. on 6ix
Earlier from North China Pharmaceutical
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Obtaining Notice of Approval for Drug Supplementary Application
- Announcement on the Release of Pledge for Shares Held by the Controlling Shareholder
- Announcement on Issuance Result of Phase I Short-term Financing Bonds in 2025
- Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Subsidiary
Later from North China Pharmaceutical
- Announcement on Receiving the Chemical Active Pharmaceutical Ingredient (API) CEP Certificate by Subsidiary
- Announcement on Implementation of Dividend Distribution for 2024
- 2025 Semi-annual Report
- Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Hebei Jurisdiction and 2025 Semi-annual Report Collective Performance Briefing
- Indicative Announcement on Postponing Election of Board of Directors at Expiry of Term of Office
Follow North China Pharmaceutical into a list and get an email when it puts out news.
Follow North China Pharmaceutical